REGENXBIO Inc. financial data

Symbol
RGNX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9804 Medical Center Drive, Rockville, Maryland
Fiscal year end
December 31
Former names
ReGenX Biosciences, LLC (to 11/7/2013)
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 310 % -7.5%
Debt-to-equity 70.2 % +14.5%
Return On Equity -68.2 % -21.3%
Return On Assets -40.1 % -15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.4M shares +12.4%
Common Stock, Shares, Outstanding 49.3M shares +13.1%
Entity Public Float 805M USD -18.3%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 50.6M shares +16.2%
Weighted Average Number of Shares Outstanding, Diluted 50.6M shares +16.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 89M USD -8.18%
Research and Development Expense 218M USD -10.9%
General and Administrative Expense 79.3M USD -10.3%
Costs and Expenses 338M USD -7.46%
Operating Income (Loss) -249M USD +7.21%
Nonoperating Income (Expense) 7.54M USD +191%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -264M USD +5.98%
Income Tax Expense (Benefit) -41K USD -1125%
Net Income (Loss) Attributable to Parent -241M USD +12.1%
Earnings Per Share, Basic -5.26 USD/shares +16.8%
Earnings Per Share, Diluted -5.26 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 57.8M USD -15.8%
Marketable Securities, Current 233M USD -7.51%
Cash, Cash Equivalents, and Short-term Investments 327M USD -21.2%
Accounts Receivable, after Allowance for Credit Loss, Current 22.8M USD +6.68%
Other Assets, Current 23.5M USD +5.67%
Assets, Current 347M USD -8.48%
Property, Plant and Equipment, Net 124M USD -10.6%
Operating Lease, Right-of-Use Asset 56.3M USD -9.76%
Other Assets, Noncurrent 2.95M USD -23.1%
Assets 569M USD -16.6%
Accounts Payable, Current 16.4M USD +40.6%
Employee-related Liabilities, Current 12.4M USD -9.97%
Contract with Customer, Liability, Current 21K USD -95.3%
Liabilities, Current 98.3M USD -16.6%
Operating Lease, Liability, Noncurrent 78.2M USD -8.23%
Other Liabilities, Noncurrent 3.53M USD -42%
Liabilities 221M USD -20.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.27M USD +77.6%
Retained Earnings (Accumulated Deficit) -821M USD -41.5%
Stockholders' Equity Attributable to Parent 348M USD -14.2%
Liabilities and Equity 569M USD -16.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -55.5M USD +31.5%
Net Cash Provided by (Used in) Financing Activities 121M USD
Net Cash Provided by (Used in) Investing Activities 13.2M USD -79.1%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 49.3M shares +13.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 78.5M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.8M USD -15.6%
Deferred Tax Assets, Valuation Allowance 280M USD +32.8%
Deferred Tax Assets, Gross 324M USD +24.9%
Operating Lease, Liability 89.3M USD -5.81%
Payments to Acquire Property, Plant, and Equipment 557K USD -88.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -233M USD +13.5%
Lessee, Operating Lease, Liability, to be Paid 1.5M USD
Property, Plant and Equipment, Gross 189M USD +0.37%
Operating Lease, Liability, Current 7.3M USD +15.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.8M USD +3.94%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9M USD +5.33%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33M USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +1.43%
Deferred Tax Assets, Operating Loss Carryforwards 61.9M USD +143%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 100K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10M USD -19.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 43.3M USD -9.91%
Share-based Payment Arrangement, Expense 37.6M USD -9.11%
Interest Expense 5.41M USD -61.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%